{ "week": "2026-W37", "label": "Week 37 \u2014 September 13\u201319, 2026", "week_start": "2026-09-13", "generated": "2026-09-14", "stats": { "total_entries": 1285, "new_this_week": 47, "compounds_represented": 6 }, "by_compound": { "psilocybin": [ { "id": "05c7b974af42d4f39abcf088f130f42fec994035cd7a233a976b08f08d3761bf", "title": "[The use of psychedelics in psychiatry].", "compound": "psilocybin", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-13", "abstract": "Over the past five years, the literature on the psychiatric use of psychedelic and related treatments has expanded substantially. Several randomized controlled trials and pooled analyses have been conducted in mood disorders, treatment-resistant depression, and post-traumatic stress disorder.\u2026", "outcome_summary": null, "doi": "10.1556/650.2026.33665", "url": "https://pubmed.ncbi.nlm.nih.gov/42732542/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Psychedelic use in psychiatry for mood disorders and PTSD.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "1ccc0a5eca4d87b7d0e32b1e03f95c58d7cebe5dd70a744336cd5b878ed44c1e", "title": "What Is Psilocybin?", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-09-10", "abstract": "This JAMA Patient Page describes the psychedelic compound psilocybin, its medical and recreational use, and its potential side effects.", "outcome_summary": null, "doi": "10.1001/jama.2026.18064", "url": "https://pubmed.ncbi.nlm.nih.gov/42721017/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Describes psilocybin, its medical use, and side effects.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "e525c4fbe413bd6f26b97514290220a78eb24ea4522be47730877599b16a7fef", "title": "Psilocybin.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-10", "abstract": "This JAMA Insights discusses the medical use of psilocybin, particularly for depression treatment, including emerging potential indications, safety, and future use.", "outcome_summary": null, "doi": "10.1001/jama.2026.11874", "url": "https://pubmed.ncbi.nlm.nih.gov/42720966/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Psilocybin for depression treatment, safety, and future use.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "1805c5d3cc3ebcc3bf49ebb90ececc774ae41a1305c120475caf62a5653920a8", "title": "Craving Reduction and Smoking Outcomes in Psilocybin-Assisted and Standard Cessation Care.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "addiction", "sample_size": null, "status": "published", "date": "2026-09-09", "abstract": "Smoking cessation outcomes are heterogeneous, and factors associated with these differences are not fully understood.\u2026", "outcome_summary": null, "doi": "10.47626/1516-4446-2026-5060", "url": "https://pubmed.ncbi.nlm.nih.gov/42715291/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Psilocybin-assisted therapy for smoking cessation.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "7cb9912de2b21e9fa3f971bea110ac64bb90e4fbcf761acafcc7045c9e46ca84", "title": "Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.", "compound": "psilocybin", "type": "observational", "institution": "Pontif\u00edcia Universidade Cat\u00f3lica do Rio de Janeiro", "condition": "other", "sample_size": 100, "status": "recruiting", "date": "2026-04-01", "abstract": "Self-awareness, the capacity of becoming the object of one's own awareness, is a frontier of scientific knowledge.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07732166", "source": "ClinicalTrials.gov", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Human study on psilocybin and self-awareness.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "5b345ab7da46f66376b175581a2c13e382a774102bdf7eb20203d8dd45955520", "title": "Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder", "compound": "psilocybin", "type": "phase_2", "institution": "Brugmann University Hospital", "condition": "addiction", "sample_size": 62, "status": "active", "date": "2024-02-15", "abstract": "Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06160232", "source": "ClinicalTrials.gov", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Psilocybin for alcohol use disorder, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "94aa1df2d320061b691901acb87ffb332607c54a2d18b8a3527b4cb84f73d5c9", "title": "Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD", "compound": "psilocybin", "type": "observational", "institution": "Tel-Aviv Sourasky Medical Center", "condition": "PTSD", "sample_size": 13, "status": "recruiting", "date": "2025-07-22", "abstract": "This is an open-label pilot study designed to evaluate the safety, tolerability, and preliminary clinical effects of psilocybin-enhanced trauma-focused psychotherapy in individuals with post-traumatic stress disorder (PTSD).\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07737054", "source": "ClinicalTrials.gov", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Psilocybin for PTSD treatment in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "c671cce4a532a7d4e6d0ab3814fa269269e2dab8d874bd98d09742afbe4c15b0", "title": "Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia", "compound": "psilocybin", "type": "phase_2", "institution": "Kevin Boehnke", "condition": "other", "sample_size": 17, "status": "completed", "date": "2023-09-27", "abstract": "The pressing need for effective fibromyalgia (FM) treatments, the known safety of psilocybin therapy, and the mechanistic plausibility for potential benefit provide a backdrop for investigating psilocybin therapy as a treatment for FM.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05128162", "source": "ClinicalTrials.gov", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Psilocybin for chronic pain (fibromyalgia) in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "261a980c2dc5b7f3f1b7b82ec7ea088b3b93fc45fcb286f2774283983d6f6082", "title": "Identification of a Safe and Non-Psychedelic Dose of Psilocybin", "compound": "psilocybin", "type": "phase_1", "institution": "Diamond Therapeutics Inc.", "condition": "other", "sample_size": 56, "status": "completed", "date": "2021-10-19", "abstract": "This randomized, double-blind, placebo-controlled, single ascending dose study will evaluate psilocybin in healthy adult subjects.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07710027", "source": "ClinicalTrials.gov", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Healthy volunteers studying psilocybin dose-finding.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "14ae6e04563f8ee227e631b6530014911310b70eb281ab1a37d1db13cb559949", "title": "Distinct brain responses to psilocybin and escitalopram in depression captured by the Fluctuation-Dissipation Theorem", "compound": "psilocybin", "type": "preprint", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-06-16", "abstract": "In recent decades, the psychedelic psilocybin has been studied as a potential treatment for major depressive disorder (MDD), offering an alternative to traditional antidepressants. However, the brain changes underlying the clinical effects of different interventions remain unclear.\u2026", "outcome_summary": null, "doi": "10.64898/2026.06.12.731811", "url": "https://doi.org/10.64898/2026.06.12.731811", "source": "bioRxiv/medRxiv", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Psilocybin for depression, comparing to traditional antidepressants.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "c6d15fc4df1e3cf3ec3a2c0654f9636e3144a54c84072efc5657dc000fcddb51", "title": "Compass Pathways\u2019 New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year", "compound": "psilocybin", "type": "phase_3", "institution": "Compass Pathways plc", "condition": "depression", "sample_size": 258, "status": "published", "date": "2026-09-09", "abstract": "These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected; the full results and safety data from our Phase 3 clinical trials in TRD may not be consistent with the topline results; our need for [...] COMP360\u2019s highly differentiated clinical profile.\u2026", "outcome_summary": "Topline 52-week results from the Phase 3 COMP005 trial of COMP360 (psilocybin) for treatment-resistant depression showed additional benefit with a single 25 mg dose, extending durability out to 1 year. The safety profile was consistent with previous parts of the trial.", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx", "source": "Compass Pathways", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Phase 3 trial of psilocybin for treatment-resistant depression", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "2dbc1c14c1503d4f6c49d27a3d86716d83293ce39625e1ea744695d102f01efd", "title": "Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026", "compound": "psilocybin", "type": "news", "institution": "Compass Pathways plc", "condition": "depression", "sample_size": null, "status": "other", "date": "2026-09-08", "abstract": "These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected; the full results and safety data from our Phase 3 clinical trials in TRD may not be consistent with the preliminary results; our need for substantial additional funding to achieve our business [...] that preliminary results will be predictive of full safety and efficacy data from our phase 3 program; the potential for our current or any future clinical trials to support regulatory filings and approvals for COMP360 psilocybin treatment on an accelerated basis or at all; our ability to obtain regulatory approval and adequate coverage and reimbursement; our ability to transition from a clinical-stage to a commercial-stage organization and effectively launch a commercial product, if regulatory [...] although not all forward-looking statements contain these words.\u2026", "outcome_summary": "Compass Pathways announced its participation at Psych Congress 2026, where it will debut an educational campaign for U.S. HCPs focused on TRD and present new HEOR data. The company will also feature encore presentations from its COMP360 psilocybin clinical development program.", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-to-Debut-U-S--HCP-Education-Campaign-and-Present-New-HEOR-Data-at-Psych-Congress-2026/default.aspx", "source": "Compass Pathways", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Company news about psilocybin for TRD", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "5f972ea335f958c60ad996ac730b3788e84ac73a31fe27ed38c922f7452470f0", "title": "Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training", "compound": "psilocybin", "type": "news", "institution": "Compass Pathways plc", "condition": "depression", "sample_size": null, "status": "other", "date": "2026-09-10", "abstract": "These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected; our need for substantial additional funding to achieve our business goals and if we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or [...] to delay, limit or terminate our clinical trials; our efforts to obtain marketing approval from the applicable regulatory authorities in any jurisdiction for our investigational COMP360 psilocybin treatment may be unsuccessful; our efforts to commercialize and obtain coverage and reimbursement for our investigational COMP360 psilocybin treatment, if approved, may be unsuccessful; the risk that this U.S.\u2026", "outcome_summary": "Compass Pathways announced recipients of a U.S. grant program to develop training for healthcare providers involved in psychedelic treatments, such as COMP360 psilocybin. These programs aim to provide foundational training and prepare providers for the expected commercial launch of COMP360.", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-U-S--Grant-Program-Recipients-for-the-Development-of-Post-Approval-COMP360-Provider-Training/default.aspx", "source": "Compass Pathways", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Industry news about psychedelic treatment training programs.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "681b3aa423197efc7dff7a39d70f53fc39e0abeccbe599d455ec9fb287e39081", "title": "New Phase 2 Clinical Trial Initiating in 2027 Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "recruiting", "date": "2026-09-10", "abstract": "References 1. Optimi Health to initiate phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder. News release. September 10, 2026. Accessed September 10, 2026. 2. FDA accelerates action on treatments for serious mental illness following executive order.\u2026", "outcome_summary": "A new Phase 2 clinical trial is set to begin in 2027 to evaluate the efficacy and safety of psilocybin-assisted therapy for individuals with major depressive disorder.", "doi": null, "url": "https://www.psychiatrictimes.com/view/new-phase-2-clinical-trial-initiating-in-2027-evaluating-psilocybin-assisted-therapy-for-major-depressive-disorder", "source": "General News", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Psilocybin for major depressive disorder is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "9539e8575c6c6d92644a0070ce81a1cf930ad92020a2040bcc8d9f4eddc77231", "title": "Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial", "compound": "psilocybin", "type": "phase_2", "institution": "Center for Psychedelic Drug Research and Education", "condition": "PTSD", "sample_size": 12, "status": "completed", "date": "2026-07-30", "abstract": "Reprints and permissions ## About this article Check for updates. Verify currency and authenticity via CrossMark ### Cite this article Armstrong, S.B., Levin, A.W., Sepeda, N.D. et al.\u2026", "outcome_summary": "Psilocybin-assisted therapy was found to be safe and well-tolerated in U.S. military Veterans with severe, treatment-resistant PTSD. The trial showed a significant reduction in PTSD symptoms, with 75% of participants achieving a treatment response or remission.", "doi": "10.1038/s43856-026-01767-4", "url": "https://www.nature.com/articles/s43856-026-01767-4", "source": "General News", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Psilocybin for PTSD in veterans", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "84ff312eddc3a7aca42ffc59e9caa1ab012198ddd827f7c7b9e602496afafc56", "title": "5 Best Psychedelic Stocks for 2026 and How to Invest", "compound": "psilocybin", "type": "phase_3", "institution": "Atai", "condition": "depression", "sample_size": null, "status": "recruiting", "date": "2026-07-10", "abstract": "Helus Pharma's lead candidate is HLP003 (formerly known as CYB003), a deuterated version of psilocin, a psychedelic found in mushrooms. The company expects to report results from one phase 3 study of HLP003 as an adjunct treatment of major depressive disorder in the fourth quarter of 2026.\u2026", "outcome_summary": "Atai plans Phase 3 tests for depression treatments after a merger. Compass Pathways is advancing a psilocybin therapy into late-stage clinical trials for PTSD.", "doi": null, "url": "https://www.fool.com/investing/stock-market/market-sectors/healthcare/psychedelic-stocks", "source": "General News", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Industry news and clinical trials for depression and PTSD.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "f19834219638fe7007418bbf05931633649826bf5a271a45baef28792b8af58d", "title": "Psilocybin FDA Priority Review 2026: Compass Pathways Depression, PTSD Approval", "compound": "psilocybin", "type": "regulatory", "institution": "Compass Pathways", "condition": "depression", "sample_size": null, "status": "approved", "date": "2026-06-17", "abstract": "On April 24, 2026, the U.S.\u2026", "outcome_summary": "Compass Pathways' COMP360 psilocybin therapy has received FDA priority review for treatment-resistant depression and PTSD. The FDA's decision is expected by 2026.", "doi": null, "url": "https://www.medicaldaily.com/psilocybin-fda-priority-review-2026-compass-pathways-depression-ptsd-approval-475666", "source": "General News", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Psilocybin therapy for depression and PTSD, FDA priority review.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } } ], "mdma": [ { "id": "c614d7e5354ee0288bcb75fd0c4e72902d282545a09183b26dd8c46de45d1af8", "title": "MDMA-Assisted Therapy May Decrease PTSD Symptoms, Dissociation, Depression, and Functional Disability: A Systematic Review and Meta-Analysis.", "compound": "mdma", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-09", "abstract": "There is a need for new effective treatment options for posttraumatic stress disorder (PTSD), as many people with PTSD do not fully recover despite current treatments. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) is emerging as a new treatment option.\u2026", "outcome_summary": null, "doi": "10.1097/HRP.0000000000000478", "url": "https://pubmed.ncbi.nlm.nih.gov/42708350/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "MDMA-assisted therapy for PTSD is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } } ], "ketamine": [ { "id": "83310567a029bbc30914c296b243c72466dc404f2ec597a30e1ac06641f7dbce", "title": "A rapid systematic review of palliative uses of ketamine for depression and pain in people living with advanced cancer.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-03", "abstract": "Given the growing population of patients living with metastatic cancer, palliative care providers need every available tool for symptom management. We conducted a rapid review of the literature on palliative uses of ketamine for pain and depression in people with cancer.\u2026", "outcome_summary": null, "doi": "10.21037/apm-2026-0032", "url": "https://pubmed.ncbi.nlm.nih.gov/42733004/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Palliative uses of ketamine for depression and pain in cancer patients.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "55c808e0d1935e3f60a93cb064846ca2f1dc9be9e91262baf3f8eb12f5de370d", "title": "Beyond symptom reduction: Intranasal esketamine is associated with improved quality of life in treatment-resistant depression.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-07", "abstract": "Treatment-resistant depression (TRD) is associated with severe functional impairment, poor quality of life, and increased suicide risk.\u2026", "outcome_summary": null, "doi": "10.1016/j.jpsychires.2026.09.005", "url": "https://pubmed.ncbi.nlm.nih.gov/42731235/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Intranasal esketamine for treatment-resistant depression quality of life.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "daf9780b613f075d9e2d505119b84fa45ec7d7a80ed471c4426a685e1156e821", "title": "Management of Neuropathic Pain in Complex Regional Pain Syndrome: A Comprehensive Review.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-11-01", "abstract": "Complex regional pain syndrome (CRPS) is a complex and multifaceted condition in which pain may be neuropathic, nociplastic, nociceptive, or mixed in nature.\u2026", "outcome_summary": null, "doi": "10.1111/papr.70197", "url": "https://pubmed.ncbi.nlm.nih.gov/42725581/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Review of neuropathic pain treatment, a relevant chronic pain indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "2997d923f90c15b91799d92fb2bcf6c97ffee85a635e0d1196462fad10d2286c", "title": "Ketamine: from anesthesia to pediatric suicidal crisis.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-09-01", "abstract": null, "outcome_summary": null, "doi": "10.1007/s43678-026-01261-9", "url": "https://pubmed.ncbi.nlm.nih.gov/42722964/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Ketamine for pediatric suicidal crisis is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "940d70ab319f509b33dd4a30dc0a092e7fdd2014000f197c24be6802d49c7be1", "title": "Non-randomized rapamycin augmentation of chronic self-administered ketamine provides subjective improvement in diverse phenotypes.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "addiction", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "Multiple preclinical and clinical reports suggest that rapamycin augmentation may increase the safety and efficacy of ketamine treatment.\u2026", "outcome_summary": null, "doi": "10.3389/fpsyt.2026.1910337", "url": "https://pubmed.ncbi.nlm.nih.gov/42719198/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Rapamycin augmentation of chronic ketamine for subjective improvement.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "a1c9c13f5693b12ba87dbdf70c703fbd01b731dab83384229138573c0468b4ef", "title": "Ketamine-Induced Dissociation as an Ethical Signal, Not a Side Effect: Context as the Determinant of Clinical Duties Under Beneficence and Non-maleficence.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-09-09", "abstract": "Ketamine has emerged as an important intervention in contemporary psychiatry, yet its acute dissociative effects remain ethically under-theorized.\u2026", "outcome_summary": null, "doi": "10.1007/s10730-026-09611-x", "url": "https://pubmed.ncbi.nlm.nih.gov/42717138/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Ketamine for psychiatric treatment, ethical considerations.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "da331ac2ba9f6f3a802a8592e6ff97f366e7f998f26eafa638dafe842276dae0", "title": "Bridging the gut and mind: a narrative review of depression in Crohn's disease and emerging gut-brain axis therapies.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "Depression is a highly prevalent and clinically significant comorbidity in Crohn's disease (CD), a form of inflammatory bowel disease (IBD), and is associated with increased disease activity, hospitalization, and a reduced quality of life (QoL).\u2026", "outcome_summary": null, "doi": "10.3389/fnins.2026.1920926", "url": "https://pubmed.ncbi.nlm.nih.gov/42707773/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Depression is a psychiatric indication, and gut-brain axis therapies are relevant.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "7dddcde9c6f9e78a5c1b2be234417aa325300500a7b0c71edf2988b3a5be3a0e", "title": "Is (S)-norketamine an active mediator of esketamine's antidepressant effects?", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-07", "abstract": null, "outcome_summary": null, "doi": "10.1038/s41380-026-03867-y", "url": "https://pubmed.ncbi.nlm.nih.gov/42706419/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Investigational treatment for depression", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "ecb359c6235b048254ec74f219a99fafb136e739496905352e3bbb5b2d014417", "title": "The Antidepressant Effects of the mGlu2/3 Receptor Antagonist TS-161 in Treatment-Resistant Depression: A Phase IIa Proof-of-Concept Clinical Trial.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-07", "abstract": "Like ketamine, group II metabotropic glutamate receptor (mGluR2/3) antagonists increase glutamate release and monoaminergic signaling, promote synaptic plasticity, and show antidepressant-related activity in preclinical models.\u2026", "outcome_summary": null, "doi": "10.1097/JCP.0000000000002246", "url": "https://pubmed.ncbi.nlm.nih.gov/42704784/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Antidepressant effects of a novel compound in a clinical trial.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "2d2d4d63c0874971ed9621f398b9d1139d1929a73f4e70ce5bc65fbd45a28858", "title": "Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression", "compound": "ketamine", "type": "phase_1", "institution": "National Institute of Mental Health (NIMH)", "condition": "depression", "sample_size": 70, "status": "recruiting", "date": "2020-01-21", "abstract": "Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work. A drug that blocks these receptors might affect how it works.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03973268", "source": "ClinicalTrials.gov", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Mechanism of action of ketamine for depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "789ae5c40070f539c30dc987bcefa096dc2be29bc015beedd8d2adbac201d514", "title": "Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.", "compound": "ketamine", "type": "observational", "institution": "Sunnybrook Health Sciences Centre", "condition": "depression", "sample_size": 9, "status": "completed", "date": "2016-01-01", "abstract": "Depression and suicidal ideation/attempt/death are major causes of morbidity and mortality from psychiatric illnesses. In 2009, the World Health Organization listed depression as the leading cause of years lost due to disability worldwide.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02593643", "source": "ClinicalTrials.gov", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Ketamine for depression and suicidal ideation in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "ad36b89678280310eccd1b4b12f827b703d7546423b082f3e66488bd19dcbed5", "title": "Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression", "compound": "ketamine", "type": "observational", "institution": "Massachusetts General Hospital", "condition": "depression", "sample_size": 20, "status": "recruiting", "date": "2026-04-17", "abstract": "This study is being conducted at Massachusetts General Hospital (MGH) to explore whether adding psychedelic coaching can enhance the effects of ketamine or esketamine maintenance treatment in individuals with treatment-resistant depression (TRD).\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07563868", "source": "ClinicalTrials.gov", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Ketamine therapy for treatment-resistant depression with coaching.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "35a121d6f0b172c840b9a16d8dfb89a6ab7b7f1057a388f593d7a8e362e80c7d", "title": "Neuropathic Pain Caused by Radiation Therapy", "compound": "ketamine", "type": "phase_3", "institution": "British Columbia Cancer Agency", "condition": "other", "sample_size": 22, "status": "completed", "date": "2008-04-01", "abstract": "To investigate if topical amitriptyline 2%, ketamine 1%, and lidocaine 5% in pluronic lecitine organogel (AKL in PLO gel) can improve management of neuropathic pain from radiation skin reactions adjunctively or better than standard treatment.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT00798083", "source": "ClinicalTrials.gov", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Investigates ketamine for chronic neuropathic pain treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "07345ad3fe0b331babe5566c3ff7df5807b7736b098905ed2f05fc0793e14628", "title": "Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain", "compound": "ketamine", "type": "phase_3", "institution": "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center", "condition": "other", "sample_size": 106, "status": "completed", "date": "2017-05-01", "abstract": "This is a prospective, randomized controlled trial which will be conducted to determine whether sub-dissociative dose ketamine (SDDK) can improve pain control in subjects with chronic pain syndrome presenting to the emergency department with exacerbation of their chronic pain.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02920528", "source": "ClinicalTrials.gov", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Subdissociative ketamine for acute exacerbation of chronic pain.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "5271f35ec96f3c7f3aee1ba38ce7b9939e37ab3d534abace2dc9b0defa92ad81", "title": "Pharmacologic Treatment Augmentation in Chronic Depression", "compound": "ketamine", "type": "phase_2", "institution": "University Hospital Tuebingen", "condition": "depression", "sample_size": 60, "status": "recruiting", "date": "2024-04-29", "abstract": "To enroll in this clinical trial, prospective participants must meet stringent criteria. The participants need to fall within the age range of 18 to 64 and exhibit chronic depression at therapy resistance stage 2.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06410599", "source": "ClinicalTrials.gov", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Chronic depression is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "684081cb24aacd48d65f9af163c437f9de86ac2fcc8b91ad280bc621b50abdf2", "title": "54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide", "compound": "ketamine", "type": "phase_3", "institution": "Janssen Research & Development, LLC", "condition": "depression", "sample_size": 226, "status": "completed", "date": "2017-06-09", "abstract": "The purpose of the study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03039192", "source": "ClinicalTrials.gov", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Esketamine for major depressive disorder with suicidal ideation.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "360816328fde52c72c6d5157a3ab35c1a1762f31dbcacb173d2b9924362fc87b", "title": "A Study of HR071603(Ketamine Nasal Spray) in Healthy Subjects", "compound": "ketamine", "type": "phase_1", "institution": "Jiangsu HengRui Medicine Co., Ltd.", "condition": "depression", "sample_size": 50, "status": "completed", "date": "2019-10-24", "abstract": "The study is being conducted to evaluate the safety and pharmacokinetics of HR071603 in healthy subjects.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04108234", "source": "ClinicalTrials.gov", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Safety and pharmacokinetics in healthy subjects.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "fd14c545503d633eff12a24314930057caf272fae9e10a8e0885bbac2e7807fd", "title": "Effects of TS-134 on Ketamine-induced BOLD Signals in Healthy Subjects", "compound": "ketamine", "type": "phase_1", "institution": "Taisho Pharmaceutical R&D Inc.", "condition": "other", "sample_size": 63, "status": "completed", "date": "2017-06-28", "abstract": "The purpose of this study is to evaluate the effects of TS-134 on ketamine-induced BOLD signals in ROIs in resting fMRI in healthy adult subjects.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03141658", "source": "ClinicalTrials.gov", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Human study on ketamine's effects on brain signals.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "cd442811836bc55cdd38ac26593988d82ecf42825a0cb41ee77f08e3de63d97f", "title": "Ketamine in the Treatment of Suicidal Depression", "compound": "ketamine", "type": "observational", "institution": "New York State Psychiatric Institute", "condition": "depression", "sample_size": 82, "status": "completed", "date": "2012-06-01", "abstract": "This study is designed to compare the effectiveness of two medications, Ketamine and Midazolam, for rapidly relieving suicidal thoughts in people suffering from depression.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01700829", "source": "ClinicalTrials.gov", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Ketamine for suicidal depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "ddd78d32d970506f29d3eacc2bf7d5cbe446a3fac49d39d282c5de4b51f354bb", "title": "Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder", "compound": "ketamine", "type": "phase_2", "institution": "VA Connecticut Healthcare System", "condition": "depression", "sample_size": 5, "status": "completed", "date": "2016-05-01", "abstract": "To evaluate if naltrexone plus ketamine is effective in reducing depression and alcohol consumption.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03658330", "source": "ClinicalTrials.gov", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Treating depression and alcohol use disorder with ketamine.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "c71126c6a4c55304820aac7d2affcc69fa676723ffbf9b9e0301be6a96b378c5", "title": "Ketamine reveals shifting brain activity patterns linked to depression improvement in older adults", "compound": "ketamine", "type": "observational", "institution": "Texas A&M University", "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-12", "abstract": "Other collaborators in the study were Rahul Balakrishnan and Baylor College of Medicine professors Dr. Alan C. Swann and Dr. Brittany O'Brien.\u2026", "outcome_summary": "Researchers identified time-specific patterns of brain activity following ketamine treatment in older adults with treatment-resistant depression. These findings could help identify biological markers associated with ketamine's antidepressant effects and explain differing patient responses.", "doi": "10.1038/s41398-026-04212-1", "url": "https://medicalxpress.com/news/2026-09-ketamine-reveals-shifting-brain-patterns.html", "source": "General News", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant depression in older adults.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "b638b069833a52ebefeecccf455038b89331c1ef0825bd3473ce88be75783475", "title": "Ketamine Safely Reduces Symptoms of Treatment-Resistant Bipolar Depression", "compound": "ketamine", "type": "news", "institution": null, "condition": "depression", "sample_size": null, "status": "other", "date": "2025-05-08", "abstract": "# Ketamine Safely Reduces Symptoms of Treatment-Resistant Bipolar Depression ## Repeated ketamine infusions reduced depression scores in treatment-resistant bipolar depression.\u2026", "outcome_summary": "A study found that ketamine infusion safely and rapidly reduced depressive symptoms in patients with treatment-resistant bipolar depression. The treatment was well-tolerated, with no serious adverse events reported.", "doi": null, "url": "https://www.technologynetworks.com/tn/news/ketamine-safely-reduces-symptoms-of-treatment-resistant-bipolar-depression-416429", "source": "General News", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant bipolar depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "f5a34d5cc186ac47f1ec4073a2ca647a952642edb7379167e55fedf09da6a303", "title": "Ketamine: How Yale redefined depression treatment", "compound": "ketamine", "type": "news", "institution": "Yale", "condition": "depression", "sample_size": null, "status": "other", "date": "2026-02-24", "abstract": "The results of studies on esketamine were remarkable. Clinical trials showed that esketamine was effective even for patients who had not responded to multiple prior treatments.\u2026", "outcome_summary": "Yale researchers have been instrumental in redefining depression treatment through their work with ketamine, exploring its rapid antidepressant effects and mechanisms.", "doi": null, "url": "https://medicine.yale.edu/news-article/ketamine-how-yale-redefined-depression-treatment", "source": "General News", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Ketamine used for depression treatment in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } } ], "dmt": [ { "id": "61fb2547136047031824808548090e9d5d432d57f3e35d8b01812894b7b939d0", "title": "Higher signal diversity, network dysregulation, and increased well-being under DMT administration: An EEG study.", "compound": "dmt", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-09-07", "abstract": "N,N-Dimethyltryptamine (DMT), a potent serotonin-2A receptor agonist, elicits intense psychedelic experiences and has become a focus of interest in neuroscience and mental health research.\u2026", "outcome_summary": null, "doi": "10.1016/j.brainres.2026.150530", "url": "https://pubmed.ncbi.nlm.nih.gov/42705377/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "EEG study on DMT and well-being in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "a89ce106acba056647b82e4621945d349ccb38d0fce2348b75f288eafce840b9", "title": "Exploratory Insights into 5-MeO-DMT Experiences on Reddit: A Thematic Analysis.", "compound": "dmt", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-09-07", "abstract": "This qualitative study examines self-reported experiences with 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) shared on Reddit to explore subjective reports, contextual influences, and perceived effects.\u2026", "outcome_summary": null, "doi": "10.1080/02791072.2026.2727030", "url": "https://pubmed.ncbi.nlm.nih.gov/42704210/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Qualitative study of 5-MeO-DMT experiences on Reddit.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } } ], "ayahuasca": [ { "id": "6293559f8649324d99b0a04932827e1725a09e57894fced5cd3def2b1f9da065", "title": "Brazil's Federal Public Prosecutor's Office Recommends New Regulations for Ayahuasca and DMT", "compound": "ayahuasca", "type": "regulatory", "institution": "Federal Public Prosecutor\u2019s Office (MPF)", "condition": "other", "sample_size": null, "status": "recruiting", "date": "2026-09-11", "abstract": "

On September 2, 2026, the Federal Public Prosecutor\u2019s Office (MPF) in Acre issued Recommendations Nos.\u2026", "outcome_summary": "The Federal Public Prosecutor\u2019s Office (MPF) in Acre has issued recommendations to CONAD and Anvisa proposing the creation of working groups to gather information and formulate new parameters for the regulation of ayahuasca and DMT. These agencies have thirty days to respond.", "doi": null, "url": "https://chacruna.net/brazil-mpf-ayahuasca-dmt-regulations/", "source": "Chacruna Institute", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Regulatory news regarding ayahuasca and DMT in Brazil.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "c4a9af18ee63eece2c1d50bf9c15cea8ea449b23dd03f76fbeda26777c8fd3ee", "title": "Paulo Roberto Silva e Souza\u2019s Acquittal and the Ongoing Reckoning Within Santo Daime", "compound": "ayahuasca", "type": "news", "institution": "C\u00e9u do Mar Church", "condition": "other", "sample_size": null, "status": "approved", "date": "2026-09-10", "abstract": "

A Santo Daime padrinho\u2019s trial and acquittal raise questions about systemic issues in the church.

After a monthslong trial that attracted high-level media attention and international coverage, Paulo Roberto Silva e Souza, the founder of Rio de Janeiro\u2019s influential C\u00e9u do Mar Church, was acquitted by a judge in May. 

During the trial, which began in January, Silva e Souza faced charges of sexual violation by fraud and psychological abuse.\u2026", "outcome_summary": "Paulo Roberto Silva e Souza, founder of Rio de Janeiro's C\u00e9u do Mar Church, was acquitted of sexual violation by fraud and psychological abuse charges in May. The public prosecutor's office is appealing the decision, and controversy continues regarding allegations of abuses of power within the Santo Daime community.", "doi": null, "url": "https://chacruna.net/paulo-roberto-silva-e-souza-ceu-do-mar-acquittal/", "source": "Chacruna Institute", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Legal and policy news regarding a psychedelic religious practice.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } } ], "other": [ { "id": "12cf79072821209b4cfc4c0e69a88d7ec5ef3bc4f9f9625bc6cf7c27ea19b5d9", "title": "Characterizing Psychedelic-Evoked Familiarity: A Comparative Study with Autobiographical and D\u00e9j\u00e0 Vu Experiences.", "compound": "other", "type": "phase_2", "institution": null, "condition": "anxiety", "sample_size": null, "status": "published", "date": "2026-09-11", "abstract": "Psychedelic experiences often evoke a sense of familiarity, an experiential quality that has received little empirical attention despite its potential therapeutic and cognitive significance.\u2026", "outcome_summary": null, "doi": "10.1080/02791072.2026.2729618", "url": "https://pubmed.ncbi.nlm.nih.gov/42725633/", "source": "PubMed", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "Psychedelic experiences and their phenomenology are within scope.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } }, { "id": "f6995a523a3f9c116eafba4e9c134afb9223dbfabea707ed290e057d832618c5", "title": "What FDA\u2019s July 2026 Psychedelic Drug Guidance Actually Says About Trial Design", "compound": "other", "type": "regulatory", "institution": null, "condition": "other", "sample_size": null, "status": "other", "date": "2026-09-12", "abstract": "1. NEJM, \u201cFDA\u2019s New Framework for Psychedelic Drugs,\u201d Volume 395, Issue 10, September 10, 2026 2. FDA, \u201cPsychedelic Drugs: Considerations for Clinical Investigations,\u201d Final Guidance, July 2026 3. Nature Medicine, MAPP2 Phase 3 MDMA-Assisted Therapy Trial Results 4.\u2026", "outcome_summary": null, "doi": null, "url": "https://www.clinicaltrialvanguard.com/opinion/what-fdas-july-2026-psychedelic-drug-guidance-actually-says-about-trial-design", "source": "General News", "first_seen": "2026-09-14", "relevance": { "relevant": true, "reason": "FDA guidance on psychedelic drug trial design", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-09-14" } } ] } }